Page 1

RENISHAW apply innovation ™ Trading Statement Released : 21 Oct 2021 RNS Number : 7378P Renishaw PLC 21 October 2021 Renishaw plc Trading update 21 October 2021 Renishaw plc , the global provider of manufacturing technologies , analytical instruments and medical devices , publishes this trading update for the three months ended 30 September 2021. It contains unaudited information that covers the first quarter of the financial year and the period since . Trading activity Manufacturing technologies Analytical instruments and medical devices Total Revenue Adjusted * Profit before tax Statutory Profit before tax 3 months to 3 months to 30 30 September September 2020 2021 £ 148.5m £ 9.3m £ 157.8m Outlook £ 41.7m £ 39.3m £ 111.2m £ 5.7m £ 116.9m £ 18.3m £ 28.2m Change + 34 % + 63 % + 35 % Group revenue for the first quarter of the current financial year was £ 157.8m , compared to £ 116.9m for the corresponding period last year . We have experienced strong revenue growth in all our regions following an improvement to global macroeconomic conditions over the last year . In our Manufacturing technologies business ( formerly Metrology ) revenue amounted to £ 148.5m , compared to £ 111.2m last year , with the strong growth driven largely by demand from the semiconductor and electronics markets . In our Analytical instruments and medical devices business ( formerly Healthcare ) revenue was £ 9.3m , compared with £ 5.7m last year . Adjusted * profit before tax for the first quarter amounted to £ 41.7m compared with £ 18.3m last year and the statutory profit before tax amounted to £ 39.3m ( 2020 : £ 28.2m ) . Financial position The Group balance sheet remains strong with net cash and bank deposit balances of £ 234.8m at 30 September 2021 ( 30 June 2021 : £ 215.0m ) . The 2022 financial year has started with a strong first quarter and we currently have a record order book . We expect demand from the semiconductor and electronics sectors to remain strong and that there will continue to be a recovery in the machine tool and co - ordinate measuring machine markets . In our Analytical instruments and medical devices markets , we have seen confidence return and capital expenditure projects released . The Board continues to be confident in our long - term prospects , due to our strong financial position , the high quality of our people , our innovative product pipeline , extensive global sales and marketing presence and relevance to high - value manufacturing . Th results for the half year ending 31 December 2021 are expected to be released on 3 February 2022 .